PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
P/B ratio for PainReform Ltd. (PRFX)
P/B ratio as of 2023: 0.50
According to PainReform Ltd.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.50. At the end of 2022 the company had a P/B ratio of 2.40.
P/B ratio history for PainReform Ltd. from 2017 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.50 |
| 2022 | 2.40 |
| 2021 | 4.33 |
| 2020 | 18.90 |
| 2019 | -66.95 |
| 2018 | -52.58 |
| 2017 | -6.35 |